ABSTRACT
Serosurveillance studies are critical for estimating SARS-CoV-2 transmission and immunity, but interpretation of results is currently limited by poorly defined variability in the performance of antibody assays to detect seroreactivity over time in individuals with different clinical presentations. We measured longitudinal antibody responses to SARS-CoV-2 in plasma samples from a diverse cohort of 128 individuals over 160 days using 14 binding and neutralization assays. For all assays, we found a consistent and strong effect of disease severity on antibody magnitude, with fever, cough, hospitalization, and oxygen requirement explaining much of this variation. We found that binding assays measuring responses to spike protein had consistently higher correlation with neutralization than those measuring responses to nucleocapsid, regardless of assay format and sample timing. However, assays varied substantially with respect to sensitivity during early convalescence and in time to seroreversion. Variations in sensitivity and durability were particularly dramatic for individuals with mild infection, who had consistently lower antibody titers and represent the majority of the infected population, with sensitivities often differing substantially from reported test characteristics (e.g., amongst commercial assays, sensitivity at 6 months ranged from 33% for ARCHITECT IgG to 98% for VITROS Total Ig). Thus, the ability to detect previous infection by SARS-CoV-2 is highly dependent on the severity of the initial infection, timing relative to infection, and the assay used. These findings have important implications for the design and interpretation of SARS-CoV-2 serosurveillance studies.
Competing Interest Statement
M-AP, AV, MAR, JP, JH are employees of Abbott Laboratories. LT, TW, and CJP are employees of Monogram Biosciences, Inc., a division of LabCorp. C.Y.C. is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC) and receives research support funding from the Abbott Laboratories Inc.TJH reports grants from Merck and Co., Gilead Biosciences, and Bristol-Myers Squibb outside the submitted work. MJP, ST, JH, JDK, LT, NSI, KT, OJ, SEM, CT, CCN, RH, VT, EF, YH, MAS, MG, SKE, XXZ, JAW, AS, TWK, JEP, WW, RLR, JNM, SGD, IRB, and BG have no interests to declare.
Clinical Trial
NCT04362150
Funding Statement
Funding: This work was supported by the National Institute of Allergy and Infectious Diseases (NIH/NIAID 3R01AI141003-03S1 [to TJ Henrich], NIH/NIAID R01AI158013 [to M Gandhi and M Spinelli] and by the Zuckerberg San Francisco Hospital Department of Medicine and Division of HIV, Infectious Diseases, and Global Medicine. MJP is supported on NIH T32 AI60530-12 and by the UCSF Resource Allocation Program. ST is supported by the Schmidt Science Fellows, in partnership with the Rhodes Trust. IRB and ST acknowledge research funding from the MIDAS Coordination Center COVID-19 Urgent Grant Program (MIDASNI2020-5). PDB is supported by the Intramural Research Program of the National Institute of Dental Research and JIC is supported by the National Institute of Allergy and Infectious Diseases. CYC is supported in part by NIH grants R01 HL105704 from the National Heart, Lung, and Blood Institute, R33- 29077 (C.Y.C.), and Abbott Laboratories. BG and JAW are supported in part by the Chan Zuckerberg Biohub Investigator Fund, XZ was supported by Damon-Runyon Cancer Research Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the UCSF IRB #20-30479. All subjects provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw antibody data at the participant and visit level are provided in Supplementary Tables 2 and 3.
